<?xml version="1.0" encoding="iso-8859-1" ?>
<newsitem itemid="101623" id="root" date="1996-10-08" xml:lang="en">
<title>USA: KeraVision wins FDA ok for Phase III test.</title>
<headline>KeraVision wins FDA ok for Phase III test.</headline>
<dateline>FREMONT, Calif. 1996-10-08</dateline>
<text>
<p>KeraVision Inc said Tuesday it has won U.S. Food and Drug Administration approval to begin a Phase III trial of its KeraVision Ring, a transparent, insertable ring that is designed to reduce the effect of near-sightedness.</p>
<p>The study will utilize three KeraVision Ring sizes designed to treat from -1.0 to -3.5 diopters of myopia, a range that includes an estimated 44 million Americans.</p>
<p>In Phase II tests, all the patients achieved 20/40 vision or better and 89 percent achieved 20/25 vision or better using up to -4.0 diopters of correction, KeraVision said.  </p>
<p>The KeraVision Ring, also known as the ICR Intrastromal Corneal Ring, consists of two thin, transparent half rings made of the same polymer material that has been safely used in people's eyes for over 40 years, the company said.</p>
<p>The KeraVision Ring is designed to correct nearsightedness when inserted into the periphery of the cornea by reshaping the clear tissue at the very front of the eye without cutting or removing tissue from the central optical zone.</p>
<p>The KeraVision Ring is designed to be permanent but it can also be surgically removed, which creates the possibility for reversal of refractive effect, the company said.</p>
<p>The Phase III study will involve 360 myopic eyes at up to 10 U.S. investigational medical sites. Since March 1991, there have been more than 490 KeraVision Ring procedures performed in eight countries.</p>
</text>
<copyright>(c) Reuters Limited 1996</copyright>
<metadata>
<codes class="bip:countries:1.0">
  <code code="USA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-08"/>
  </code>
</codes>
<codes class="bip:topics:1.0">
  <code code="C13">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-08"/>
  </code>
  <code code="C23">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-08"/>
  </code>
  <code code="CCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-08"/>
  </code>
  <code code="GCAT">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-08"/>
  </code>
  <code code="GHEA">
    <editdetail attribution="Reuters BIP Coding Group" action="confirmed" date="1996-10-08"/>
  </code>
</codes>
<dc element="dc.date.created" value="1996-10-08"/>
<dc element="dc.publisher" value="Reuters Holdings Plc"/>
<dc element="dc.date.published" value="1996-10-08"/>
<dc element="dc.source" value="Reuters"/>
<dc element="dc.creator.location" value="FREMONT, Calif."/>
<dc element="dc.creator.location.country.name" value="USA"/>
<dc element="dc.source" value="Reuters"/>
</metadata>
</newsitem>
